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Detection and Characterization of VIM-31, a New Variant of VIM-2
with Tyr224His and His252Arg Mutations, in a Clinical Isolate of
Enterobacter cloacae
Pierre Bogaerts,a Carine Bebrone,b Te-Din Huang,a Warda Bouchahrouf,a Yves DeGheldre,c Ariane Deplano,d Kurt Hoffmann,b and
Youri Glupczynskia
Laboratory of Bacteriology, CHU Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgiuma; Institute of Molecular Biotechnology, RWTH-Aachen University,
Aachen, Germanyb; Laboratory of Bacteriology, CHIREC-Edith Cavell Hospital, Brussels, Belgiumc; and Laboratory of Bacteriology, Erasme-ULB University Hospital, Brussels,
Belgiumd
We report the first description of the metallo--lactamase VIM-31, a new variant of VIM-2 with Tyr224His and His252Arg mu-
tations, in Enterobacter cloacae 11236, which was isolated from blood specimens of a patient with colonic adenocarcinoma in
Belgium. blaVIM-31 was found on a class 1 integron located on a self-transferable but not typeable 42-kb plasmid. Compared to
values published elsewhere for VIM-2, the purified VIM-31 enzyme showed weaker catalytic efficiency against all the tested beta-
lactam agents (except for ertapenem), resulting from lower kcat (except for ertapenem) and higherKm values for VIM-31.
The worldwide spread ofmetallo--lactamases (i.e., VIM, IMP,and NDM enzymes) in carbapenem-resistant Gram-negative
bacteria presently constitutes a major public health issue.
So far, 33 distinct blaVIM alleles have been described (www
.lahey.org/Studies) for a variety of Gram-negative opportunistic
pathogens, but only VIM-1, VIM-2, VIM-4, VIM-7, and VIM-27
enzymes (7, 12, 15, 22, 31) have been characterized biochemically
and structurally. While VIM-1-derived enzymes have been re-
ported largely for Enterobacteriaceae from around the world, es-
pecially from Greece but also recently from Belgium (4), VIM-2
has been associated mostly with Pseudomonas aeruginosa (32).
The occurrence of VIM-2 has nevertheless also been reported for
clinical isolates of Enterobacteriaceae from Asia (17, 24, 39), Mex-
ico (28), Argentina (16), and Tunisia (10). Moreover, a recent
report showed the presence of VIM-2 in Enterobacter ludwigii iso-
lated from sewage water of a hospital, highlighting the involve-
ment of environmental bacteria as potential reservoirs for the dis-
semination of clinically relevant metallo--lactamase resistance
genes (37). In many subclass B1 (e.g., IMP and NDM) and B2
(e.g., CphA)metallo--lactamases, the amino acid at position 224
(a conserved Lys residue), close to the active site, plays an impor-
tant role in substrate binding (2, 27). In the case of VIM enzymes,
Lys224 is not present and is replaced by His224 in VIM-1 and by
Tyr224 in VIM-2. The side chains of histidine and tyrosine resi-
dues are much shorter than that of a lysine residue, thereby pre-
venting the interaction of these two amino acids with the carbox-
ylate moiety (C4 or C3) of the substrate. For VIM enzymes, it is
hypothesized that Arg228, with its long side chain, may replace
Lys224 in interacting with the substrate (15, 22).
We report here the detection and characterization of VIM-31,
a new variant of VIM-2 with Tyr224His and His252Arg muta-
tions, in an Enterobacter cloacae clinical isolate recovered from an
elderly patient in Belgium.
MATERIALS AND METHODS
Bacterial strains and antimicrobial susceptibility. Enterobacter cloacae
11236 was recovered in June 2011 from blood culture specimens from a
patient hospitalized in Brussels, Belgium. The isolate was identified to the
species level by matrix-assisted laser desorption ionization–time of flight
mass spectrometry (MALDI-TOF MS) with a Microflex LT mass spec-
trometer (Bruker Daltonik GmbH, Leipzig, Germany). Susceptibility to
antimicrobials was determined by the disc diffusionmethod, andMICs of
antimicrobial agents were determined by Etest (bioMérieux, Marcy
l’Etoile, France) or broth microdilution (Sensititre; Trek Diagnostic Sys-
tems, Cleveland, OH) according to CLSI guidelines (11). EDTA-disc syn-
ergy tests were performed for the screening of metallo--lactamase pro-
duction (4).
PCR detection of bla genes and sequencing. Detection of extended-
spectrum -lactamase (ESBL) genes (blaTEM,SHV, blaCTX-M-1-like,
blaCTX-M-2-like, blaCTX-M-9-like, and blaCTX-M-8/25/26-like) and of carbapen-
emase genes (blaVIM, blaIMP, blaNDM-1, blaOXA-48, and blaKPC) was per-
formed byDNAmicroarray analysis (Check-MDRCT102; Check-Points,
Wageningen, The Netherlands) according to a previously described pro-
tocol (30). blaOXA-1-like, blaOXA-2-like, and blaOXA-10-like genes, genes en-
coding class A ESBL enzymes (BEL, GES, VEB, and PER), and qnr genes,
involved in quinolone resistance, were detected by PCR as previously
described (3, 6). The genetic context of blaVIM-31 was assessed by PCR
amplification and sequencing of the variable region of the integron by
using primers designed on the basis of the 5= and 3= conserved segments of
the class 1 integron (25), using an external sequencing service (Macrogen,
Seoul, South Korea). Nucleotide sequences were analyzed with the
BLASTNalgorithm, available from theNational Center for Biotechnology
Information website (http://www.ncbi.nlm.nih.gov/BLAST/).
Molecular typing. Pulsed-field gel electrophoresis (PFGE) analysis of
XbaI-digested genomic DNAwas used to examine the genetic relatedness
of E. cloacae 11236 to other E. cloacae isolates known to be epidemic in
several Belgian hospitals (A. Deplano, personal data). PFGE patterns were
analyzed with BioNumerics software (AppliedMaths, Kortrijk, Belgium),
using the Dice similarity coefficient and the unweighted-pair group
methodusing average linkages (UPGMA) as previously described (5). The
PFGE classification criteria were described previously, and similar PFGE
types included patterns showing differences of 0 to 6DNA fragments (38).
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Plasmid analysis, mating assay, and electroporation experiments.
Plasmid DNA was extracted by the Kieser method (18) or by use of a
QIAfilter PlasmidMidi kit (Qiagen, Venlo, The Netherlands). Escherichia
coli NCTC50192, harboring four plasmids, of 154, 66, 48, and 7 kb, was
used as a plasmid sizemarker. PlasmidDNAwas analyzed by 0.7%agarose
gel electrophoresis. Determination of the incompatibility groups of plas-
mids was done as described by Carattoli et al. (8). Transfer of the -lac-
tamase genes from E. cloacae 11236 to Escherichia coli J53 (azide resistant)
and Pseudomonas aeruginosa PU21 (rifampin resistant) was attempted by
solid and liquid mating assays at 37°C (13). Selection was performed on
brain heart infusion (BHI) agar plates supplementedwith ticarcillin at 100
g/ml and azide at 150 g/ml for E. coli and with ticarcillin at 100 g/ml
and rifampin at 100 g/ml for P. aeruginosa. Moreover, plasmid DNA
extracts from E. cloacae 11236 were electroporated into E. coliTOP10 cells
(Invitrogen, Merelbeke, Belgium) by use of a Gene Pulser II apparatus
(Bio-Rad, Marnes-la-Coquette, France) as previously described (1, 9),
and transformants were selected on BHI agar plates containing 100g/ml
of ticarcillin. Electroporation of a plasmidic extract of E. cloacae 11236
into Pseudomonas aeruginosa PAO1 was also performed as previously de-
scribed (13), and transformants were selected on BHI agar plates contain-
ing 100 g/ml of ticarcillin or 20 g/ml of tobramycin.
Cloning of blaVIM-31.The blaVIM genewas amplifiedwithHotStarTaq
DNA polymerase (Qiagen, Venlo, The Netherlands) according to the
manufacturer’s instructions, using primers 5=-CATGCCATGGTCAAAC
TTTTGAGTAAGTTATTG-3= and 5=-CTGAATTCCTACTCAACGACT
GAGCGATTTGTG-3=, designed to add NcoI and EcoRI restriction sites
(underlined in the sequences) upstream and downstream of the VIM-31
gene, respectively. The PCR product was then cloned into pET-28a (No-
vagen, Madison, WI), and the expression vector construct, named pET-
28a/VIM-31, was introduced into E. coli BL21(DE3) (New England Bio-
Labs, Ipswich,MA) by electroporation. The construct was verified by PCR
and sequencing with primers targeting the T7 RNA polymerase promoter
and terminator.
Production andpurification.pET-28a/VIM-31-expressingE. coliwas
grown overnight at 37°Cwith shaking in 50ml LBmedium supplemented
with 50 g/ml kanamycin. The bacterial suspension was diluted 100-fold
in a total of 2 liters of Terrific Broth supplemented with kanamycin (50
g/ml), and the expression of VIM-31 was induced with isopropyl--D-
thiogalactopyranoside (final concentration, 1 mM) when the culture
reached an A600 of 0.6. The induced culture was incubated overnight at
28°C with shaking.
VIM-31 was purified by ion-exchange chromatography and gel filtra-
tion. Briefly, the bacterial suspension was pelleted, resuspended in 60 ml
of buffer A (50 mMHEPES, pH 7.5, 50 MZnCl2), disrupted by sonica-
tion, and cleared by ultracentrifugation. The supernatant was then dia-
lyzed against buffer A and loaded onto a Q-Sepharose FF column equili-
brated with the same buffer. The proteins were eluted with a linear NaCl
gradient (0 to 1 M). Fractions were analyzed by SDS-PAGE and by the
ability to hydrolyze nitrocefin. Those fractions containing -lactamase
activity were pooled and dialyzed against buffer A overnight at 4°C. This
partially purified enzyme was loaded onto aMonoQ column (GEHealth-
care, Diegem, Belgium) equilibrated with the same buffer. The proteins
were eluted with a linear gradient of NaCl (0 to 0.5 M). The fractions
containing -lactamase activity were pooled and concentrated to a vol-
ume of 2 ml. Size-exclusion chromatography was performed on a Hiload
16/60 Superdex 75 preparation-grade column (GE Healthcare, Diegem,
Belgium) equilibrated with buffer A supplemented with 250 mM NaCl.
Finally, fractions containing the highest -lactamase activities were
pooled and subsequently dialyzed overnight at 4°C against buffer A. The
VIM-31 enzyme was 95% pure as judged by SDS-PAGE (data not
shown).
Determination of kinetic parameters. All experiments were per-
formed at 30°C in buffer A in the presence of 50MZn2 (22). Imipenem
and ertapenem were obtained from Merck Sharp and Dohme Research
Laboratories (Rahway, NJ). Ampicillin, benzylpenicillin, piperacillin,
cephalothin, cefoxitin, cefotaxime, ceftazidime, cefepime, meropenem,
and aztreonam were obtained from Sigma-Aldrich (Steinheim, Ger-
many). Nitrocefin was a gift from ProGenosis (Liége, Belgium). Hydroly-
sis of the antibiotics wasmonitored by following the absorbance variation
resulting from the opening of the -lactam ring, using a Uvikon 943
spectrophotometer equipped with thermostatically controlled cells. The
wavelengths and extinction coefficients used were those previously re-
ported (21, 33) for all drugs tested except for ertapenem (36). The kcat and
Km parameters were determined under initial rate conditions, using the
Hanes linearization of the Henri-Michaelis-Menten equation.
Homology model. A homology model of VIM-31 was constructed
using the EsyPred3D server (www.fundp.ac.be/urbm/bioinfo/esypred),
based on the structure of reduced VIM-2 (Protein Data Bank [PDB] ac-
cession number 1KO3).
Nucleotide sequence accession number. The nucleotide sequence
data reported in this paper have been assigned to the EMBL/GenBank
nucleotide sequence database under accession number JN982330. VIM
numbering was assigned according to the method of the Lahey clinic.
RESULTS AND DISCUSSION
Clinical isolate, susceptibility profile, and patient outcome. In
June 2011, an 87-year-old female underwent a left hemicolectomy
for intestinal adenocarcinoma. Her immediate postoperative sta-
tus was complicated by the occurrence of a deep surgical site in-
fection, for which she received a 2-week course of antimicrobial
treatment, first comprising piperacillin-tazobactam and then
comprisingmeropenem. Six days after the end therapy, she devel-
oped a peritonitis caused by a carbapenem-resistant Enterobacter
cloacae isolate (E. cloacae 11236) as suspected by Vitek2 (mero-
penem MIC of 16 mg/liter and imipenem MIC of 4 mg/liter
[data not shown]).
Etest MIC determination (Table 1) confirmed that E. cloacae
11236 was intermediately susceptible to imipenem (MIC 3 g/
ml) and resistant to ertapenem (MIC 6 g/ml), but it was sus-
ceptible to meropenem (MIC  0.5 g/ml) and also to aztreo-
nam, tigecycline, amikacin, and ciprofloxacin. The presence of a
metallo--lactamase in this isolate was suspected by a positive
double-disc synergy test with imipenem and EDTA.
The patient gradually improved following a 9-day course of
treatment with ciprofloxacin (400 mg twice daily [BID] intrave-
nously for 3 days, followed by 500 mg BID orally for 6 days), but
she remained persistently colonized with E. cloacae 11236 in the
urine for several weeks and returned home.
-Lactamase genes, genetic support transfer, and typing.
Analysis of -lactamase-encoding genes detected the presence of
blaVIM in addition to blaCTX-M of group 9. PCR amplification and
sequencing of the blaVIM-bearing integron (In669 [GenBank ac-
cession no. JN982330]; the integron number was assigned by
INTEGRALL, the integron database [29]) revealed the presence of
a new blaVIM-31 allele located upstream of the aacA4 allele. The
blaVIM/aacA4 structure of In669 was found to match almost per-
fectly with a VIM-2-harboring integron described for an Acineto-
bacter sp. isolate in Korea (GenBank accession no. EF125009),
except for three single nucleotide polymorphisms (one upstream
and twowithin blaVIM-2), as well as with the first 2 cassettes of In71
in P. aeruginosa TS-832347 (GenBank accession no. AM180753)
(20), recovered in Italy. blaVIM-31 differs from blaVIM-2 by two
single nucleotide polymorphisms, resulting in Tyr224His and
His252Arg mutations according to the class B standard number-
ing of Garau et al. (14). Additional PCR amplification and se-
quencing revealed the presence of blaCTX-M-9 and qnrA1 in E. clo-
Bogaerts et al.
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acae 11236. Plasmid extracts showed the presence of three
plasmids, of ca. 290, 136, and 42 kb, with the latter (p11236) being
a blaVIM-31-harboring nontypeable plasmid (8) which could be
transferred by electroporation into E. coliTOP10 (not shown) and
also by mating experiments into E. coli J53 (Table 1). Despite
several attempts, p11236 could not be transferred to P. aeruginosa
PAO1 or PU21, suggesting that it was not self-replicative in P.
aeruginosa. Molecular detection of the resistance genes in the E.
coli transformant (E. coli TOP10/p11236) and transconjugant (E.
coli J53/p11236) confirmed that blaVIM-31 was not located on the
same plasmid as the qnrA1 and blaCTX-M-9 genes (data not shown).
TheVIM-31-expressing E. coli J53 transconjugant displayed lower
MICs, especially for cephalosporins, monobactam, and carbapen-
ems (Table 1). Regarding carbapenems, this suggests that reduced
outer membrane permeability could also contribute to decreased
susceptibility or to resistance to carbapenems in this clinical iso-
late, as already demonstrated (23). According to PFGE analysis, E.
cloacae 11236 corresponds to a sporadic isolate and does not clus-
terwith any of themajorCTX-M-9-producingE. cloacae epidemic
clones identified previously in Belgian hospitals (35; data not
TABLE 1 Etest or microdilution MICs of E. cloacae 11236, E. coli J53 (ECJ53) and E. coli BL21 (ECBL21) acceptor strains, a transconjugant, and





J53 J53/p11236c BL21d BL21/pET-28a/VIM-31 BL21/pET-28a/VIM-2
Ticarcillin 256 1.5 256 1.5 256 256
Ticarcillin-clavulanate 256 1.5 256 1.5 256 256
Temocillin 192 4 256 3 32 64
Piperacillin 96 0.75 32 0.75 12 12
Piperacillin-tazobactam 24 1.5 16 0.75 8 16
Ceftazidime 4 0.125 1.5 0.064 0.5 2
Cefepime 2 0.064 0.5 0.064 0.19 0.19
Aztreonam 1 0.032 0.032 0.0016 0.016 0.016
Imipenem 3 0.19 1 0.25 0.75 1
Meropenem 0.5 0.032 0.125 0.023 0.064 0.125
Ertapenem 6 0.032 0.38 0.064 0.125 0.19
Doripenem 0.5 0.016 0.094 0.032 0.094 0.125
Amikacin 4 4 4 NA NA NA
Gentamicin 4 1 2 NA NA NA
Tobramycin 8 1 4 NA NA NA
Ciprofloxacin 0.5 0.25 0.25 NA NA NA
Tigecycline 0.25 0.25 0.25 NA NA NA
Colistin 0.25 0.25 0.25 NA NA NA
a MICs were evaluated by Etest for ticarcillin to doripenem and by microdilution for amikacin to colistin. NA, not analyzed.
b Strain isolated from blood culture and harboring blaVIM-31, blaCTX-M-9, aacA4=, and qnrA1.
c The plasmid p11236 (42 kb) harbored blaVIM-31 and aacA4= but not blaCTX-M-9 and qnrA1.
d The MICs observed for E. coli BL21 were identical to those for the strain transformed with the original (without VIM) pET28a vector. The selection marker for pET28a was
kanamycin.
TABLE 2 Kinetic parameters of VIM-31 and VIM-2 enzymes
Antibiotic
VIM-31 parametersa VIM-2 parametersb
Ratio of kcat/Km for VIM-2
to kcat/Km for VIM-31kcat (s
1) Km (M) kcat/Km (mM
1 s1) kcat (s
1) Km (M) kcat/Km (mM
1 s1)
Benzylpenicillin 108 270 400 280 70 4,000 10
Ampicillin 36 40 900 125 90 1,400 1.6
Piperacillin 66 72 920 300 125 2,400 2.6
Cefotaxime 62 32 1,900 70 12 5,800 3
Ceftazidime 2.2 490 4.5 3.6 72 50 11
Cefepime 8.5 470 18 40 400 100 5.6
Cefoxitin 1.6 74 22 15 13 1,200 54
Cephalothin 88 20 4,400 130 11 12,000 2.7
Nitrocefin 152 35 4,350 770 18 43,000 9.9
Imipenem 12 5 2,400 34 9 3,800 1.6
Meropenem 0.9 3 300 5 2 2,500 8.3
Ertapenem 0.6 9 67 0.2 9 22 0.33
Aztreonam 0.01 1,000 0.01 0.01 1,000 0.01
a Data are the means for three independent experiments. Standard deviations were within 10% of the means.
b VIM-2 values were reported by Docquier et al. (12), except for those for ertapenem (36). Experimental conditions are identical to those used in the study of Docquier et al.
Regarding ertapenem, the conditions used by Samuelsen et al. were slightly different (50 mM sodium cacodylate [pH 7.0], 100 M ZnCl2 for VIM-2) but did not involved major
discrepancies in hydrolysis efficiency.
VIM-31-Producing Enterobacter cloacae
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shown), suggesting the independent acquisition of VIM-31 by E.
cloacae 11236.
VIM-expressing clones and kinetics. MICs of VIM-31- and
VIM-2/pET-28a-expressing E. coli BL21 (Table 1) for various an-
tibiotics were not significantly different from each other, with the
single exception of ceftazidime (MIC 2 g/ml for E. coli BL21/
pET-28a/VIM-2 and MIC 0.5 g/ml for E. coli BL21/pET-28a/
VIM-31).
Under the experimental conditions employed, purified
VIM-31 (calculated pI 5.00; molecular mass 25,069 Da) hy-
drolyzed all compounds tested except for aztreonam. The individ-
ual kinetic parameters (kcat andKm) of VIM-31with several-lac-
tam substrates and a comparison with those of VIM-2 are
reported in Table 2.
The highest catalytic efficiencies for the VIM-31 enzyme were
observed for cefotaxime, cephalothin, nitrocefin, and imipenem,
while ceftazidime, cefepime, and cefoxitin were rather poor sub-
strates. With carbapenems, the kcat/Km ratios ranged from 67
mM1 s1 (ertapenem) to 2,400mM1 s1 (imipenem), resulting
from a combination of lowKm values and very low turnover rates,
a characteristic behavior of the VIM-type enzymes. Of the three
carbapenems tested, VIM-31 showed greater hydrolytic efficiency
against imipenem (Table 2), a result also reported for VIM-2 by
Docquier et al. (12) and Samuelsen et al. (36).
VIM-2 had a higher catalytic efficiency than its His224-pos-
sessing VIM-31 variant for all substrates tested, with the exception
of ertapenem, with the ratio of kcat/Km for VIM-2 to kcat/Km for
VIM-31 ranging from 1.6 (ampicillin and imipenem) to 54
(cefoxitin) (Table 2). For each individual substrate, the kcat values
determined for VIM-31 were lower than those for VIM-2 (only
1.1-fold lower for cefotaxime but up to 9-fold lower for cefoxitin).
On the other hand, theKm values for VIM-31were increased com-
pared to those for VIM-2, with the exception of those for ampicil-
lin, imipenem, and meropenem (12). VIM-31 was slightly more
efficient than VIM-2 for the hydrolysis of ertapenem, with the kcat
value determined for VIM-31 being 3-fold higher than that ob-
tained for VIM-2 by Samuelsen et al. (36) andwith theirKm values
remaining similar.
Positions of the mutations. A homology model of VIM-31
(Fig. 1) was constructed based on the structure of VIM-2 (PDB
accession no. 1KO3). The two single mutations (Tyr224His and
His252Arg) observed between VIM-31 and VIM-2 are both situ-
ated in the C-terminal part of the protein. The Tyr224His substi-
tution, also present in VIM-1, VIM-4 (22), VIM-7 (7, 36), and
VIM-12 (19), is located close to the active site and is situated on
the L3 loop (Fig. 1). Tyr224 in VIM-2 was previously suggested to
enhance the binding affinity of certain substrates, such as ceftazi-
dime (12, 15), forwhichVIM-2 exhibits a lowerKm value than that
forVIM-1 (His224) (theKm valueswere 800 and 72MforVIM-1
and VIM-2, respectively). In line with these findings, VIM-2
also exhibits higher affinity than its His224-possessing variant
for this substrate (the Km value of VIM-31 is increased 7-fold
compared to that of VIM-2). The His252Arg substitution is
situated on the 4 helix. This residue is distant from the active
site of the VIM enzyme (more than 22 Å away), and its side
chain points outside the protein surface, toward the external
solvent. This renders unlikely any interaction of Arg252 with
catalytically important residues of the protein or with the sub-
strates of the enzyme. Nevertheless, we cannot totally exclude
that the His252Arg mutation may also contribute to tuning the
metallo--lactamase activity. Indeed, observations made pre-
viously for VIM-11 and VIM-19 indicate that amino acid sub-
stitutions located outside the active site (Asn165Ser compared
to the VIM-2 sequence and Asn215Lys compared to the VIM-1
sequence, respectively) may alsomodulate the hydrolytic prop-
erties of the enzyme (26, 34).
Conclusions.Wehave characterized VIM-31, a newVIMvari-
ant closely related to VIM-2 that was detected in a clinical isolate
of E. cloacae in Belgium and located on a new integron, In669.
Comparison of the kinetic parameters of VIM-31 to those pre-
viously obtained by other groups for VIM-2 (12, 36) revealed that
VIM-31 exhibits globally lower catalytic efficiencies than those of
VIM-2 (because of lower kcat and higherKm values). This could be
explained mostly by the single Tyr224His point mutation.
From an epidemiological point of view, the low level of resis-
tance of E. cloacae 11236 to carbapenem drugs underscores the
difficulties that may be associated with the detection of such resis-
tance mechanisms in clinical practice.
FIG 1 (a) Superposition of VIM-2 and the homology model constructed for
VIM-31. Positions showing variation between VIM-2 and VIM-31 (224 and
252) are labeled in gray for VIM-2 and in cyan for VIM-31. (b) VIM-2 active
site. Zinc ions and water molecules are shown as gray and red spheres, respec-
tively. Residues are numbered according to the BBL standard numbering
scheme (14). Metal-ligand and hydrogen bonds are shown as dashed blue
lines. The side chain of His224 in the VIM-31 homology model is shown with
carbon atoms rendered in cyan. This figure was rendered using Pymol.
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